Sun Pharma Q4 profit jumps 26% but US generics drag persists

Sun Pharmaceutical Industries reported a 26% year-on-year jump in consolidated net profit to Rs 2,714 crore for Q4 FY26, with revenue rising 13% to Rs 14,611 crore. The headline numbers masked a persistent structural drag: US generics sales fell 1.1% year-on-year to $459 million. The stock dropped 2.4% to close at Rs 1,845.2 on the BSE, reflecting investor focus on the weakness in the company's largest overseas market.

For the full financial year FY26, consolidated net profit rose 5% to Rs 11,479 crore and revenue increased 11% to Rs 58,462 crore. The US market contributed about 28.8% of consolidated sales in the quarter. Full-year US sales declined 0.9% to $1,904 million from $1,921 million in FY25.

US Generics Slide: The Persistent Drag

The quarterly trajectory of Sun Pharma's US business shows a pattern of stagnation and occasional contraction. The table below tracks the year-on-year change across FY26:

Quarter	US Sales ($M)	YoY Change
Q1 FY26	473	+1.5%
Q2 FY26	496	-4.1%
Q3 FY26	477	+0.6%
Q4 FY26	459	-1.1%

Two of four quarters posted declines, and the full-year result was negative. The company attributed the weakness to generics pricing pressure, a structural issue that has plagued the US generics industry for years. Sun Pharma's 552 approved ANDAs and 122 pending filings (including 28 tentative approvals) represent a large pipeline. Approval timelines and price erosion remain headwinds.

Quarterly Filing Activity

During Q4, the company filed seven ANDAs and received approvals for two. The pipeline is deep. Conversion to revenue is slow in a market where buyers consolidate and demand price concessions.

Innovative Medicines: The Offset That Isn't Enough Yet

Sun Pharma's specialty and innovative medicines portfolio crossed the $1 billion revenue milestone in FY26, according to managing director Kirti Ganorkar. The company has been pivoting toward higher-margin specialty therapies, including Leqselvi (severe alopecia areata) and Unloxcyt (skin cancer).

Geographic Rollout Constraints

Management explicitly stated it is not factoring in any meaningful contribution from Leqselvi and Unloxcyt outside the US during FY27. Filings and approvals in international markets will take time because existing clinical data must be adapted for different geographies. The Illumya treatment has been launched in 40 countries, up from 35 a few quarters ago. The non-Illumya specialty portfolio is still in early stages.

Practical rule: When a company's largest market is shrinking, a 26% profit jump from other regions is not enough to sustain the stock. The market is pricing in the risk that US generics drag will persist until specialty revenue scales materially.

R&D Spend and Guidance: What FY27 Hinges On

Founder and executive chairman Dilip Shanghvi said consolidated R&D investment for Q4 stood at Rs 975 crore, or 6.7% of sales. Innovative R&D accounted for 36.9% of that total. The company expects FY27 R&D expenditure to remain between 6% and 7% of sales and has guided for high single-digit consolidated top-line growth in FY27, subject to regulatory and macroeconomic conditions.

The Organon Acquisition

Sun Pharma highlighted the strategic rationale behind its recent acquisition of Organon. The deal would add a biosimilars business and strengthen the innovative portfolio through Organon's women's health franchise. The combined innovative business contribution from both companies is expected to rise to nearly 26-27%. The acquisition complements Sun Pharma's existing strengths in dermatology, ophthalmology, and oncology while expanding its branded generics business globally.

Integration risk is real. The Organon deal adds complexity at a time when the core US generics business needs attention. If the combined entity fails to deliver the promised 26-27% innovative mix, the stock could face further pressure.

What Would Confirm or Weaken the Setup

Factors That Reduce Risk

Stabilization of US generics revenue: If quarterly US sales stop declining and show sequential improvement, the narrative shifts from structural decline to cyclical trough.

Leqselvi or Unloxcyt ramp in the US: Even without international contributions, faster-than-expected adoption in the domestic market would boost specialty revenue.

Organon integration milestones: Clear evidence of cost synergies and revenue accretion from the deal would support the 26-27% innovative mix target.

Factors That Worsen Risk

Further price erosion in US generics: The industry faces ongoing consolidation among buyers and FDA approval backlogs that could compress margins.

Regulatory delays for pending ANDAs: The 122 pending filings represent potential revenue. Any slowdown in approvals would extend the drag.

Execution missteps on Organon: If integration distracts management or fails to deliver the expected portfolio lift, the stock could re-rate lower.

The Next Catalyst: Q1 FY27 US Sales Print

Sun Pharma will report Q1 FY27 results in about three months. The key number to watch is US formulation sales. If they stabilize above $470 million and the innovative medicines segment continues to grow, the market may begin to discount the generics headwind. If US sales fall further, the stock could test support near Rs 1,700.

For context on how generics pricing pressures affect the broader pharma sector, see our stock market analysis.

Sun Pharma's story is a classic transition play: a generics giant trying to become a specialty leader. The Q4 numbers show the transition is underway. The US generics business remains a weight that will take time to shed. Investors should watch the quarterly US sales trajectory and the Organon integration timeline as the two most concrete markers of whether the thesis is working.